AlphAIalphai — Financial news for AI agents
finanznachrichten.deJUN 174 min read$SWBI

Smith & Wesson Brands, Inc: Smith & Wesson Brands, Inc. Reports Fourth Quarter and Full Fiscal 2026 Financial Results

Smith & Wesson Brands reported fourth-quarter fiscal 2026 results ended April 30, 2026: net sales rose to $178.4M (+26.7% y/y), gross margin to 29.8%, and GAAP EPS to $0.36 from $0.19. GAAP net income was $16.2M. Full-year net sales were $523.8M (+10.4%); GAAP EPS was $0.41. The company also authorized a $0.13 quarterly dividend.

Original reporting
finanznachrichten.de
Published Jun 17, 2026, 8:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$SWBI
Bullish
medium confidence
Mentioned
$SWBI
Relevance
8/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$SWBIBullishMed
01

Why it matters

The key tradable elements are the reported YoY growth in net sales and EPS, gross margin improvement, cash flow and debt reduction (repaid $60.0M on revolving credit facility), and a board-authorized quarterly dividend ($0.13/share) with specific record/payment dates.

02

Market read

A full earnings release with concrete financials and explicit dividend authorization provides a clear catalyst for short-term positioning and sentiment.

03

What to watch

The release emphasizes handgun shipments and NICS behavior; traders may want to watch whether the stated “healthy and slightly higher” FY2027 demand expectation is backed by any quantitative guidance in the call.

Relevance 8/10Novelty 7/10Timing: Earnings release published June 17, 2026 with conference call at 5:00 p.m. ET

Background

Smith & Wesson Brands (SWBI) released its fourth quarter and full fiscal year 2026 financial results ended April 30, 2026, including GAAP and non-GAAP metrics and capital allocation updates.

Company-level read

Ticker impact

$SWBIBullishMedium confidence
Context

Smith & Wesson reported Q4 FY2026 net sales of $178.4M (+26.7% YoY) and GAAP EPS of $0.36, plus full-year results and dividend authorization.

Expected impact

Likely positive bias for the next session(s) as traders digest stronger-than-prior-year profitability and the stated dividend per share.

Evidence & confidence

The article provides concrete quarterly and full-year financial metrics and a board-authorized $0.13 quarterly dividend with record/payment dates, which are actionable for traders; however, no guidance range or consensus comparison is provided.

Market effects

Sector

Firearms manufacturers may see read-across from reported handgun shipment strength and commentary that FY2027 demand should remain healthy.

Regional

Limited—company-specific results centered in the U.S. market and sporting goods channel inventory dynamics.

Global

Low—no international expansion or global macro/regulatory catalyst disclosed.

Counterpoint

What could challenge this read

Margin and earnings improvements may be partly influenced by non-recurring items (relocation costs, gain on real estate) and channel/inventory dynamics that could normalize.

Key entities

  • equity issuer
    Smith & Wesson Brands, Inc.

    Reported Q4 and full fiscal 2026 financial results, discussed handgun shipment drivers, and authorized a $0.13 quarterly dividend.

  • executive
    Mark Smith

    CEO quote accompanying the earnings release, framing execution and demand outlook for FY2027.

  • executive
    Deana McPherson

    CFO quote detailing Q4 revenue growth drivers (new products, handgun shipments) and NICS/channel inventory commentary.

Read at source← All news

Related articles

JUN 18
$SWBIMed

Smith & Wesson reports surge in firearms sales

Smith & Wesson reported a 27% year-over-year jump in fourth-quarter net sales to $178.4 million, citing strong handgun demand and new product rollouts, despite declining U.S. background checks. For fiscal 2026, it forecast net sales up more than 10% to $523.8 million. The company also plans major Springfield facility investments before April 2027.

boston.com4 min
JUN 18
$INTCMed

Wall Street futures bounce back as US-Iran deal optimism balances hawkish Fed

Wall Street futures rose after prior-session declines tied to expectations of further Fed rate hikes, with CME Group’s FedWatch showing a 50% chance of a 25 bp September move. Oil fell, supporting hopes inflation cools. US-Iran released an interim deal extending the ceasefire 60 days. Intel gained 8.4% on Trump’s comments about Apple chip work; Accenture fell 11.1% on a reduced revenue outlook.

freemalaysiatoday.com7 min
JUN 17
$SWBIMed

SMITH & WESSON BRANDS, INC. (SWBI): Results of Operations and Financial Condition

SMITH & WESSON BRANDS, INC. (SWBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d100270dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Smith & Wesson Brands, Inc. Reports Fourth Quarter and Full Fiscal 2026 Financial Results • Q4 Net Sales of $178.4 Million • Q4 Gross Margin of 29.8% • Q4 EPS of $0.36/Share • Q4 Cash from Operations of $74.6 million MARYVI

SEC EDGAR 8-K4 min
AUG 17
$JSPRMed

Jasper Therapeutics beats Q2 expectations but shares fall after results

Jasper Therapeutics (NASDAQ:JSPR) reported Q2 2026 adjusted loss of $0.10 per share, better than the $0.28 consensus, and a net loss of $2.8 million. Shares fell 4.24% pre-market. In July, Jasper completed an all-stock acquisition of Kira Pharmaceuticals and a $132 million private placement, extending its funding runway into 2H 2028. Pipeline updates include KP-104 Phase 2 interim data in Q4 2026 and briquilimab and KP-701 milestones in early 2027.

yahoo.com4 min